Yazar "Oroojalian, Fatemeh" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    A novel approach to glioblastoma multiforme treatment using modulation of key pathways by naturally occurring small molecules
    (Springer Basel Ag, 2025) Afshari, Amir R.; Sanati, Mehdi; Aminyavari, Samaneh; Keshavarzi, Zakieh; Ahmadi, Seyed Sajad; Oroojalian, Fatemeh; Karav, Sercan
    Glioblastoma multiforme (GBM), the fatal primary brain malignancy in adults, represents significant health challenges, and its eradication has been the ultimate goal of numerous medical investigations. GBM therapy encompasses various interventions, e.g., chemotherapy by synthetic cytotoxic agents like temozolomide (TMZ), radiotherapy, and, more recently, immunotherapy. A notable focus has been on incorporating naturally occurring substances in treating malignancies. Polyphenols and terpenoids, widely present in fruits and vegetables, constitute primary categories of agents employed for this purpose. They pose direct and indirect impacts on tumor growth and chemoresistance, mainly through impacting the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling, crucial in cellular processes, metabolism, and programmed death. This paper thoroughly discusses the biologic effects and practical application of polyphenols and terpenoids on GBM through the PI3K/Akt/mTOR signaling in vitro and in vivo.
  • [ X ]
    Öğe
    Nano-phytoconstituents: Recent advances, regulatory insights, challenges, and future horizons
    (Elsevier, 2025) Beygi, Mohammad; Oroojalian, Fatemeh; Karav, Sercan; Kesharwani, Prashant; Sahebkar, Amirhossein
    Phytoconstituents possess therapeutic potency in human diseases, including antioxidant, antitumor, antiinflammatory, and anti-microbial impacts, as well as cardioprotective and neuroprotective capabilities. Nonetheless, they suffer from shortcomings like low solubility and bioavailability, fast degradation upon administration, and elevated doses required to exert therapeutic effects, culminating in potential adverse effects. As a solution to these, nanoscale drug delivery systems (DDSs) such as polymeric nanoparticles (NPs), lipid-based NPs, protein-based NPs, etc. are currently devised to realize intended goals in herbal medicine, which critically are sustained release and targeted delivery of phytomedicines to affected sites. Current DDSs are formulated to encapsulate diverse phytochemicals, including curcumin, berberine, resveratrol, quercetin, baicalin, and rosmarinic acid. The ultimate nanoassembly affords superior properties such as protracted circulation time, sustained release, site-specific delivery, synergistic effects (with antitumor agents), and measurable diseasealleviating effects. This article covers recent progress in nanophytomedicines and explores how DDSs can enrich the therapeutic properties of these phytochemicals. Further, the present article covers the regulatory aspects and ethical issues to be reflected when devising such DDSs, as well as the current standing of nanophytoconstituents in clinical trials.